|
Post by brotherm1 on May 28, 2017 17:26:17 GMT -5
Matt said, "Our international expansion focuses on countries which have a less prolonged regulatory pathway given our US FDA approval. We are preparing filings for Brazil, Canada, Mexico, Australia, MENA, and the UAE. We are also evaluating EMA and other regions."
At the last call he said, "I can announce today that we are actually on file in one new listed country and are in later stage negotiations in number of different jurisdictions, and you'll see announcement of that one near-term. But as this typical with our past practices, we cannot to make these announcements till we actually get the approvals or sign the agreement, so stay tuned on that front as well."
brotherm1 says:
Brazil has a population of approx 208 million (all under national health care) Canada 36 million (national health care) Mexico 127 million (national health care to 51 million) Australia 24 million MENA (about 381 million but over about 23 countries) UAE 9 million (national health care)
Which one might we see an announcement about?
|
|
|
Post by mnholdem on May 28, 2017 20:05:56 GMT -5
Matt may not have mentioned every region MannKind is working on. I find it interesting when you look at Amphastar's stock chart, you'll notice AMPH share price started rallying at the same time as MNKD. Considering there are two parties to an agreement and that Amphastar has first right of refusal for sales of Afrezza in China, there are twice the opportunities for leaks. I recently started researching Amphastar more closely. Their stock price is rapidly rising, even though most analysts are pointing out Amphastar's sales and earnings have been sliding. They do have six ANDAs filed with the FDA, but the GDUFA dates (mentioned twice in AMPH's 1Q17 earnings call) are a ways out on the calendar and are not guaranteed approval. They are still working with the FDA on resolving trial protocols for Primatine Mist, which recently received another CRL. That approval, if it happens, won't happen this year.
So there's no little or no good news, yet AMPH's stock price is steadily rising. Add to this apparent contradiction the fact that Amphastar's CEO exercised more than 600,000 options a few days ago, valued at more than $7 million. I find that to be intriguing.
A partner agreement between MannKind and Amphastar for manufacturing, sales and distribution of Afrezza in China is not out of the question. IMO, it's actually a very real possibility.
|
|
|
Post by brotherm1 on May 28, 2017 20:20:05 GMT -5
Matt may not have mentioned every region MannKind is working on. I find it interesting when you look at Amphastar's stock chart, you'll notice AMPH share price started rallying at the same time as MNKD. Considering there are two parties to an agreement and that Amphastar has first right of refusal for sales of Afrezza in China, there are twice the opportunities for leaks. I recently started researching Amphastar more closely. Their stock price is rapidly rising, even though most analysts are pointing out Amphastar's sales and earnings have been sliding. They do have six ANDAs filed with the FDA, but the GDUFA dates (mentioned twice in AMPH's 1Q17 earnings call) are a ways out on the calendar and are not guaranteed approval. They are still working with the FDA on resolving trial protocols for Primatine Mist, which recently received another CRL. That approval, if it happens, won't happen this year. So there's no little or no good news, yet AMPH's stock price is steadily rising. Add to this apparent contradiction the fact that Amphastar's CEO exercised more than 600,000 options a few days ago, valued at more than $7 million. A partner agreement between MannKind and Amphastar for manufacturing, sales and distribution of Afrezza in China is not out of the question. IMO, it's actually a very real possibility. I agree. I was thinking the same in that it might be about a country other than what he mentioned. Looking at his words: "I can announce today that we are actually on file in one new listed country...". One new listed country? And seeing Dance has moved into China this past year, it would be smart to get the ball rolling over there now IMO
|
|
|
Post by brotherm1 on May 28, 2017 21:12:35 GMT -5
And the Yuan is valued 1/7 the dollar. We should be able to manufacture way cheaper in China? Should we ship the Danbury plant there?
|
|
|
Post by brotherm1 on May 28, 2017 22:10:48 GMT -5
Population of China 1.4 billion (more than 4x US pop) Over 9% of US pop diagnosed with diabetes; close to 1/2 of 1 percent type one. Other countries generally as much or greater.
|
|
|
Post by brotherm1 on May 28, 2017 22:15:05 GMT -5
We're in the first inning - with respect to population awareness with Afrezza in the US. As Mike said recently, only 90% of diabetic population is aware Afrezza is even an opton.
|
|
|
Post by brotherm1 on May 28, 2017 22:28:36 GMT -5
Adverse Event reports per brother Manngo looking good.
|
|
|
Post by deaner3 on May 28, 2017 22:29:14 GMT -5
We're in the first inning - with respect to population awareness with Afrezza in the US. As Mike said recently, only 90% of diabetic population is aware Afrezza is even an opton. Did you mean 90% or 9% ? I seriously doubt 90% have heard of it
|
|
|
Post by brotherm1 on May 28, 2017 22:35:26 GMT -5
Sorry, I'm in the process of drinking. He said 90% of diabetics in US are NOT aware it's an option. I personally think it's even higher than 90%
|
|
|
Post by deaner3 on May 28, 2017 22:39:37 GMT -5
Gotcha. That makes more sense. Had to be less than 10% know it exists.
|
|
|
Post by mnkdfann on May 29, 2017 7:10:59 GMT -5
Matt may not have mentioned every region MannKind is working on. I find it interesting when you look at Amphastar's stock chart, you'll notice AMPH share price started rallying at the same time as MNKD. Considering there are two parties to an agreement and that Amphastar has first right of refusal for sales of Afrezza in China, there are twice the opportunities for leaks. I recently started researching Amphastar more closely. Their stock price is rapidly rising, even though most analysts are pointing out Amphastar's sales and earnings have been sliding. They do have six ANDAs filed with the FDA, but the GDUFA dates (mentioned twice in AMPH's 1Q17 earnings call) are a ways out on the calendar and are not guaranteed approval. They are still working with the FDA on resolving trial protocols for Primatine Mist, which recently received another CRL. That approval, if it happens, won't happen this year. So there's no little or no good news, yet AMPH's stock price is steadily rising. Add to this apparent contradiction the fact that Amphastar's CEO exercised more than 600,000 options a few days ago, valued at more than $7 million. I find that to be intriguing. A partner agreement between MannKind and Amphastar for manufacturing, sales and distribution of Afrezza in China is not out of the question. IMO, it's actually a very real possibility. I think I have to disagree with some of that. Look at a six month chart, AMPH started rallying back in March and NOT the same time as MNKD at all. AMPH was rallying when MNKD was falling off a cliff. Furthermore, calling AMPH's movement over that period a 'rally' is generous. It was 13.75 / 14.27 on March 17 / 20 and 15.47 on May 25. It really wasn't MUCH of move, especially given the market behaviour over that period. I think AMPH was just moving up as some investors realized in advance that the core business wasn't as weak as some analysts were saying. And it did just beat the latest earnings estimates recently, so maybe they were right. AMPH did jump 1.50 on Friday ... no idea what that is about. Unless that was driven by the CEO exercising the 600,000 options you mentioned? (Some investors saw the CEO buy, then decided to buy themselves?)
|
|
|
Post by mnholdem on May 29, 2017 7:25:39 GMT -5
On the popular speculation of the United Arab Emirates: Healthcare is currently free for UAE citizens. UAE has seven Emirates
The UAE now has 40 public Hospitals, compared with only 7 in 1970. The Ministry of Health is undertaking a multimillion-dollar program to expand health facilities and hospitals, medical centres, and a trauma centre in the seven emirates. A state-of-the-art general hospital has opened in Abu Dhabi with a projected bed capacity of 143, a trauma unit, and the first home health care program in the UAE. To attract wealthy UAE nationals and expatriates who traditionally have travelled abroad for serious medical care, Dubai is developing Dubai Healthcare City, a hospital free zone that will offer international-standard advanced private healthcare and provide an academic medical training centre; completion is done and finished on 2010. 12 million people visit Dubai every year for healthcare services.
Source: en.m.wikipedia.org/wiki/Healthcare_in_the_United_Arab_Emirates
|
|
|
Post by matt on May 29, 2017 7:55:03 GMT -5
Why is everybody convinced that the unidentified Middle Eastern country is the UAE given that the company has not even hinted at that? Given the history of the company, wouldn't Israel be a more likely candidate than UAE?
|
|
|
Post by mnkdfann on May 29, 2017 7:59:20 GMT -5
Healthcare is free for UAE citizens it says. The UAE population is about 9.2 million. But only about 1.2 million of those are Emirati citizens. The vast majority are foreign workers and ex-pats, not covered by the free healthcare. Only a small fraction of the 12 million visiting Dubai for healthcare services are UAE citizens. Most are medical tourists.
|
|
|
Post by mnkdfann on May 29, 2017 8:13:05 GMT -5
Why is everybody convinced that the unidentified Middle Eastern country is the UAE given that the company has not even hinted at that? Given the history of the company, wouldn't Israel be a more likely candidate than UAE? There was that shipping quote found online supporting the UAE hypothesis. I don't see that there is much today to link / push Mannkind to Israel. Wasn't that primarily due to Al's connections / personal history? The last time Mannkind involved Israel, through the TASE offering, that actually created some bad press for Mannkind (at least in the financial press / among financial regulators there).
|
|